DLL3-CD3 Bispecific Antibody for T Cell Killing in SCLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Small cell lung cancer (SCLC) has a poor prognosis due to limited therapeutic options, with current treatments leading to chemoresistant disease and high relapse rates, and existing antibody-drug conjugate approaches face challenges with low expression levels of DLL3 and linker degradation issues.
Innovation Solution
A bispecific T cell-engaging antibody construct targeting DLL3 and CD3 is developed, utilizing a single chain format (scFv)2 to enhance tumor targeting and cytotoxicity, potentially overcoming low expression levels and linker degradation limitations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemotherapy is used to treat SCLC, then initial response rate is improved, but chemoresistance develops quickly leading to relapse
Solution Approach 1:
The patent introduces T cells as intermediary effector cells that mediate tumor cell killing through CD3 engagement. The bispecific antibody acts as a mediator that bridges tumor cells (via DLL3 binding) and T cells (via CD3 binding), enabling immune-mediated cytotoxicity instead of direct chemotherapy-induced cell death, thereby overcoming chemoresistance
Solution Approach 2:
The patent replaces the chemical mechanism of chemotherapy (direct DNA damage and cell cycle disruption) with a biological immune mechanism (T cell-mediated cytotoxicity through bispecific antibody engagement). This substitution of killing mechanism allows the system to bypass chemoresistance pathways while maintaining high initial response rates
2Productivity
If harsh chemo regimens are administered, then treatment efficacy is improved, but patient tolerance deteriorates due to comorbidities and age
Solution Approach 1:
The patent employs the patient's own immune system (T cells) to perform the therapeutic function of tumor cell killing. By harnessing endogenous immune effector cells rather than introducing exogenous toxic chemicals, the treatment achieves high efficacy while avoiding the severe systemic toxicities associated with intensive chemotherapy regimens
Solution Approach 2:
The patent fundamentally changes the therapeutic parameter from chemical cytotoxicity (chemotherapy) to immunological cytotoxicity (T cell-mediated killing). This parameter change allows for high treatment efficacy through potent immune activation while reducing harmful effects by avoiding DNA-damaging agents and their associated toxicities
3Measurement precision
If conventional monoclonal antibodies are used, then target specificity is improved, but ability to engage T cells and induce cytotoxicity is limited
Solution Approach 1:
The patent merges two separate binding functions into a single bispecific antibody molecule: specific tumor targeting via DLL3 binding and T cell engagement via CD3 binding. This merging of functions allows the single molecule to simultaneously achieve high target specificity and potent T cell-mediated cytotoxicity, overcoming the limitations of conventional monoclonal antibodies that can only perform one function
Solution Approach 2:
The bispecific antibody exhibits multi-functionality by simultaneously serving as a tumor targeting vehicle (via DLL3 specificity) and a T cell activator (via CD3 engagement). This dual functionality enables the molecule to both locate tumor cells with high specificity and trigger potent cytotoxic responses, whereas conventional monoclonal antibodies are limited to single functions
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.